Source: European Medicines Agency (EU) Revision Year: 2024 Publisher: Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Bruxelles, Belgium
Lorviqua 25 mg film-coated tablets.
Lorviqua 100 mg film-coated tablets.
| Pharmaceutical Form |
|---|
|
Film-coated tablet (tablet). Lorviqua 25 mg film-coated tablets: Round (8 mm) light pink immediate release film-coated tablet, debossed with “Pfizer” on one side and “25” and “LLN” on the other side. Lorviqua 100 mg film-coated tablets: Oval (8.5 × 17 mm) dark pink immediate release film-coated tablet, debossed with “Pfizer” on one side and “LLN 100” on the other side. |
Each film-coated tablet contains 25 mg of lorlatinib.
Excipient with known effect: Each film-coated tablet contains 1.58 mg of lactose monohydrate.
Each film-coated tablet contains 100 mg of lorlatinib.
Excipient with known effect: Each film-coated tablet contains 4.20 mg of lactose monohydrate.
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Lorlatinib |
Lorlatinib is a selective, adenosine triphosphate (ATP)-competitive inhibitor of ALK and c-ros oncogene 1 (ROS1) tyrosine kinases. |
| List of Excipients |
|---|
|
Tablet core: Microcrystalline cellulose Film-coating: Hypromellose |
OPA/Al/PVC blisters with aluminium foil backing containing 10 film-coated tablets.
Lorviqua 25 mg film-coated tablets: Each pack contains 90 film-coated tablets in 9 blisters.
Lorviqua 100 mg film-coated tablets: Each pack contains 30 film-coated tablets in 3 blisters.
Not all pack sizes may be marketed.
Pfizer Europe MA EEIG, Boulevard de la Plaine 17, 1050 Bruxelles, Belgium
EU/1/19/1355/002
EU/1/19/1355/003
Date of first authorisation: 6 May 2019
Date of latest renewal: 4 April 2023
| Drug | Countries | |
|---|---|---|
| LORVIQUA | Austria, Australia, Estonia, Spain, Finland, France, Hong Kong, Croatia, Ireland, Israel, Italy, Lithuania, Netherlands, Poland, Romania, Singapore, Turkey, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
